 |
|
|
| |
Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in HIV-Infected, Virologically
Suppressed, Black and Nonblack Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study
|
| |
| |
Reported by Jules Levin
IDWeek2017/IDSA, October 4-8, 2017, San Diego
Jason Flamm,1 Thanes Vanig,2 Joseph Gathe,3 Clifford Kinder,4 Michael Para,5 Bruce Rashbaum,6 Sorana Segal-Maurer,7 David Shamblaw,8 Michael Wohlfeiler,9 Benjamin Young,10 Christine Zurawski,11 Martin S. Rhee12
1Kaiser Permanente, Sacramento Medical Center and Medical Offices, Sacramento, CA; 2Spectrum Medical Group, P.C., Phoenix, AZ; 3Therapeutic Concepts, Houston, TX; 4The Kinder Medical Group, Miami, FL; 5The Ohio State University, Columbus, OH;
6Capital Medical Associates, Washington, DC; 7New York-Presbyterian/Queens, Flushing, NY; 8La Playa Medical Group, San Diego, CA; 9AIDS Healthcare Foundation, Miami Beach, FL; 10Apex Research Institute, Denver, CO; 11Atlanta ID Group, Atlanta, GA; 12Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
